Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

395
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
395
Urinary Tract Infection II: Pathophysiology01:25

Urinary Tract Infection II: Pathophysiology

52
The pathophysiology of urinary tract infections (UTIs) encompasses several progressive stages, beginning with bacterial colonization and culminating in potential systemic complications if untreated. UTIs are primarily initiated by bacteria, such as Escherichia coli, which often originate from the gastrointestinal tract and migrate to the urinary system through the periurethral area. This migration can occur via several routes, including improper hygiene practices, sexual activity, or...
52
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

14.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.4K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

579
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
579
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations01:26

Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations

43
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
43
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

300
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
300

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Climate Change, Environmental Risk Factors, and Gout.

Arthritis care & research·2025
Same author

Improvements in Health-Related Quality of Life With Treat-to-Target Urate-Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial.

Arthritis care & research·2025
Same author

Some More Equal Than Others: The Divergence of Cardiac Risk in the Use of Nonsteroidal Anti-Inflammatory Drugs Versus Colchicine for Treating and Preventing Gout.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Endothelial Cell and Neutrophil Activation in Untreated Intercritical Patients With Gout.

The Journal of rheumatology·2025
Same author

Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model.

Rheumatology and therapy·2025

Related Experiment Video

Updated: Sep 16, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

29.6K

Gout, Hyperuricemia, and the Intestinal Microbiome.

Nicholas Renton1, Michael H Pillinger2, Michael Toprover3,4

  • 1Division of Rheumatology, NYU Grossman School of Medicine, New York, NY, USA.

Inflammation
|July 5, 2025
PubMed
Summary
This summary is machine-generated.

Gout patients often have gut microbiome changes, including lower diversity. Probiotics and prebiotics show promise in reducing high uric acid levels and inflammation, but more research is needed.

Keywords:
ButyrateGoutHuman microbiomePrebioticsProbiotics

More Related Videos

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice
08:53

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice

Published on: December 4, 2020

6.3K
Establishment and Characterization of UTI and CAUTI in a Mouse Model
08:40

Establishment and Characterization of UTI and CAUTI in a Mouse Model

Published on: June 23, 2015

20.3K

Related Experiment Videos

Last Updated: Sep 16, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

29.6K
Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice
08:53

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice

Published on: December 4, 2020

6.3K
Establishment and Characterization of UTI and CAUTI in a Mouse Model
08:40

Establishment and Characterization of UTI and CAUTI in a Mouse Model

Published on: June 23, 2015

20.3K

Area of Science:

  • Microbiome Research
  • Gout Pathophysiology
  • Nutritional Therapeutics

Background:

  • Gout is characterized by hyperuricemia (HU) and monosodium urate crystal deposition, leading to joint inflammation and damage.
  • Emerging research focuses on the gut microbiome's role in HU and gout, exploring prebiotics and probiotics for therapeutic potential.

Purpose of the Study:

  • To review recent studies on the gut microbiome in hyperuricemia and gout.
  • To evaluate the efficacy of prebiotics and probiotics in managing gout and associated hyperuricemia.

Main Methods:

  • Review of recent scientific literature on gut microbiome alterations in gout patients.
  • Analysis of pre-clinical studies investigating probiotic and prebiotic interventions in animal models of gout.
  • Examination of short-chain fatty acid (butyrate) effects on uric acid levels and inflammation.

Main Results:

  • The 'gouty' microbiome exhibits reduced diversity, an increased Bacteroides: Firmicutes ratio, and lower levels of Akkermansia and Bifidobacterium.
  • Lactobacillus probiotics reduced serum urate (SU) and inflammation in avian models.
  • Inulin (prebiotic) and butyrate (short-chain fatty acid) showed potential in murine models to lower SU and reduce inflammation.

Conclusions:

  • Gut microbiome modulation represents a potential therapeutic avenue for gout and hyperuricemia.
  • Current evidence from human studies is limited by small sample sizes and geographical restrictions.
  • Further well-controlled studies in relevant animal models are necessary before human clinical trials can be reliably conducted.